查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1735682

全球轮状病毒疫苗市场规模（按类型、最终用户、区域范围和预测）

Global Rotavirus Vaccine Market Size By Type (Rotarix, Rotavac, RotaTeq), By End-user (Hospitals, Clinics, Academic And Research Institutions), By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

轮状病毒疫苗市场规模及预测

轮状病毒疫苗市场规模在过去几年一直保持良好成长速度，预计 2026 年至 2032 年的复合年增长率为 11.5%。

  • 轮状病毒疫苗是一种预防措施，旨在对抗轮状病毒感染，轮状病毒感染是严重腹泻和脱水的主要原因，尤其是在新生儿和幼儿中。
  • 疫苗接种可刺激免疫系统产生针对轮状病毒的抗体，从而提供对病毒的保护并减轻感染后的症状的严重程度。
  • 轮状病毒传染性极强，在托儿所和日託中心传播迅速。疫苗通常以口服液或静脉注射的方式接种。其用途广泛，可显着减少全球范围内与轮状病毒相关的住院和死亡人数。
  • 此外，广泛接种轮状病毒疫苗可以减少因该疾病造成的医疗费用和生产力损失相关的经济负担。

轮状病毒疫苗的全球市场动态

影响轮状病毒疫苗市场的关键市场动态是：

主要市场驱动因素：

  • 轮状病毒疫苗是一种预防措施，旨在对抗轮状病毒感染，轮状病毒感染是严重腹泻和脱水的主要原因，尤其是在新生儿和幼儿中。
  • 疫苗接种可刺激免疫系统产生针对轮状病毒的抗体，从而提供对病毒的保护并减轻感染后的症状的严重。
  • 轮状病毒传染性极强，在托儿所和日託中心传播迅速。疫苗通常以口服液或静脉注射的方式接种。其用途广泛，可显着减少全球范围内与轮状病毒相关的住院和死亡人数。
  • 此外，广泛接种轮状病毒疫苗可以减少因该疾病造成的医疗费用和生产力损失相关的经济负担。
  • 全球轮状病毒感染疾病负担：轮状病毒是全球新生儿和幼儿严重腹泻的主要原因。轮状病毒感染疾病的发生率和死亡率较高，推动了市场对有效疫苗接种计划的需求。
  • 政府措施和疫苗接种计划：许多政府和国际卫生组织正在积极推广轮状病毒疫苗作为其国家免疫方案的一部分。此类支援可能包括财政援助、宣传宣传活动以及将其纳入公共卫生计划，这将大幅提升疫苗接种覆盖率和市场成长。
  • 疫苗研发的进步：持续的研发投入已带来更新、更有效的轮状病毒疫苗的上市，这些疫苗具有更高的血清型覆盖率和效力。这些创新将提高疫苗接种的接受度和普及率，从而推动市场成长。
  • 医疗基础设施和认知度的提升：随着全球医疗基础设施的改善，尤其是在开发中国家，疫苗接种服务正变得越来越普及。此外，大众对轮状病毒疫苗益处的认识不断提高，也刺激了市场的成长。

主要挑战

  • 低温运输物流与储存：轮状病毒疫苗需要持续冷藏才能维持效力，这在低温运输基础设施有限的地区构成了重大挑战。这种限制减少了疫苗的获取，并增加了疫苗的浪费率，尤其是在资源匮乏的地区。
  • 高成本和可负担性：轮状病毒疫苗价格高昂，尤其是中低收入国家，难以推广。可负担性限制了其被纳入国家和个人免疫接种及医疗保健计划，从而限制了市场扩张。
  • 与其他医疗保健重点衝突：在许多地区，尤其是在医疗资源匮乏的地区，轮状病毒疫苗的优先顺序并不高于其他基本卫生措施。这些衝突推迟了轮状病毒疫苗计画的引入和推广，并限制了其市场渗透率。

主要趋势

  • 新型候选疫苗的开发：目前，开发具有更强效力、更安全、覆盖范围更广的新型轮状病毒疫苗的趋势十分显着。这些进展旨在突破现有疫苗的局限性，同时满足不同族群尚未满足的需求。
  • 更关注中低收入国家：国际卫生组织和疫苗製造商越来越重视透过协商价格、与当地製造商合作以及资助免疫计划，促进轮状病毒病最为流行的中低收入国家获得轮状病毒疫苗。
  • 纳入国家免疫计划：轮状病毒疫苗正在被纳入世界各地的国家免疫计划，因为越来越多的证据表明轮状病毒疫苗在减轻疾病负担方面有效，这鼓励各国政府将轮状病毒疫苗纳入常规儿科护理。

目录

第一章轮状病毒疫苗全球市场介绍

  • 市场概览
  • 研究范围
  • 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

  • 资料探勘
  • 验证
  • 第一手资料
  • 资料来源列表

第四章全球轮状病毒疫苗市场展望

  • 概述
  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
  • 波特五力模型

5. 全球轮状病毒疫苗市场（按类型）

  • 概述
  • 罗塔里克斯
  • 旋转背
  • RotaTech
  • 其他的

6. 全球轮状病毒疫苗市场（依最终用户）

  • 概述
  • 医院
  • 诊所
  • 学术/研究
  • 其他的

7. 全球轮状病毒疫苗市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 世界其他地区
    • 拉丁美洲
    • 中东和非洲

8. 全球轮状病毒疫苗市场竞争格局

  • 概述
  • 各公司市场排名
  • 主要发展策略

第九章 公司简介

  • Merck & Co.
  • GlaxoSmithKline plc.
  • Beijing Wantai Biological Pharmacy Enterprise Co.
  • Walvax Biotechnology Co.
  • Bharat Biotech International Limited
  • Institute of Vaccines and Medical Biologicals
  • Serum Institute of India Pvt. Ltd.
  • Chengdu Institute of Biological Products Co
  • Incheon Vaccines Ltd
  • Deyuan Biotech Group Co.

第十章 重大进展

  • 产品发布/开发
  • 合併与收购
  • 业务扩展
  • 伙伴关係与合作

第十一章 附录

  • 相关调查
简介目录
Product Code: 35692

Rotavirus Vaccine Market Size And Forecast

The Rotavirus Vaccine Market size is growing at a good pace over the last few years and is expected to grow at a CAGR of 11.5% from 2026 to 2032.

  • The rotavirus vaccine is a preventive measure intended to combat rotavirus infection, a leading cause of severe diarrhea and dehydration, particularly in newborns and young children.
  • The vaccination stimulates the immune system to develop antibodies against rotavirus, giving protection against the virus and decreasing the severity of symptoms if infected.
  • Rotavirus is very contagious and spreads quickly in daycare centers and nurseries. The vaccination is usually given orally, either as a liquid or as oral drops, which makes it convenient for newborns. Its applications are numerous, as it greatly reduces the number of rotavirus-related hospitalizations and fatalities globally.
  • Furthermore, widespread rotavirus immunization can reduce the economic burden associated with medical expenses and missed productivity due to illness.

Global Rotavirus Vaccine Market Dynamics

The key market dynamics that are shaping the Rotavirus Vaccine Market include:

Key Market Drivers:

  • The rotavirus vaccine is a preventive measure intended to combat rotavirus infection, a leading cause of severe diarrhea and dehydration, particularly in newborns and young children.
  • The vaccination stimulates the immune system to develop antibodies against rotavirus, giving protection against the virus and decreasing the severity of symptoms if infected.
  • Rotavirus is very contagious and spreads quickly in daycare centers and nurseries. The vaccination is usually given orally, either as a liquid or as oral drops, which makes it convenient for newborns. Its applications are numerous, as it greatly reduces the number of rotavirus-related hospitalizations and fatalities globally.
  • Furthermore, widespread rotavirus immunization can reduce the economic burden associated with medical expenses and missed productivity due to illness.
  • Global Burden of Rotavirus Infections: Rotavirus is a major cause of severe diarrhea in newborns and young children worldwide. Rotavirus infections have a high incidence rate, as well as significant morbidity and mortality, which drives market demand for effective immunization programs.
  • Government Initiatives and Immunization Programs: Many governments, along with international health organizations, are aggressively promoting rotavirus vaccines as part of their national immunization regimens. This support includes funding, awareness campaigns, and inclusion in public health programs, which will dramatically increase vaccination adoption and market growth.
  • Advancements in Vaccine Development: Continuous research and development efforts have resulted in the launch of newer, more effective rotavirus vaccines with greater serotype coverage and efficacy. These innovations improve vaccination acceptance and adoption, accelerating market growth.
  • Increasing Healthcare Infrastructure and Awareness: Immunization services are becoming more widely accessible as the world's healthcare infrastructure, especially in developing nations, gets better. In addition, increasing public awareness of the benefits of rotavirus vaccine stimulates market growth.

Key Challenges:

  • Cold Chain Logistics and Storage: Rotavirus vaccines require continual refrigeration to retain efficacy, which presents a substantial issue in areas with limited cold chain infrastructure. This constraint reduces vaccine accessibility and raises waste rates, especially in low-resource settings.
  • High Costs and Affordability: Rotavirus vaccinations are prohibitively expensive, particularly in low- and middle-income countries, making widespread adoption challenging. Affordability constraints limit governments' and individuals' abilities to include these vaccinations in national immunization programs or personal healthcare plans, limiting market expansion.
  • Competition with Other Healthcare Priorities: The Rotavirus vaccine is not prioritized over other essential health measures in many locations, particularly in areas with little healthcare resources. This competition for resources and attention slows the introduction and expansion of rotavirus vaccine programs, limiting market penetration.

Key Trends:

  • Development of New Vaccine Candidates: There is a significant trend toward the development of novel rotavirus vaccines with stronger efficacy, better safety profiles, and broader strain coverage. These advancements attempt to solve current vaccine limitations while also meeting unmet requirements in a variety of populations.
  • Growing Focus on Low- and Middle-Income Countries: International health organizations and vaccine producers are focusing more on boosting access to rotavirus vaccines in low- and middle-income countries, where rotavirus disease is most prevalent. Price negotiations, local manufacturing partnerships, and immunization program funding are among the efforts being made.
  • Integration with National Immunization Programs: Rotavirus vaccine is increasingly being integrated into national immunization programs around the world. This integration is aided by expanding evidence of the vaccination's effectiveness in reducing disease burden, which encourages governments to incorporate the vaccine into routine pediatric care.

Global Rotavirus Vaccine Market Regional Analysis

Here is a more detailed regional analysis of the Rotavirus Vaccine Market:

North America:

  • According to VMR Analyst, North America is estimated to dominate the Rotavirus Vaccine Market during the forecast period. North America, particularly the United States, has a well-established healthcare infrastructure. This allows for widespread vaccine distribution and delivery, ensuring high immunization coverage and boosting market growth in this region.
  • Rotavirus vaccine is actively supported by government health agencies in North America, which provide advice, financing, and inclusion in national immunization programs. These measures increase vaccine adoption, which contributes greatly to market domination.
  • North Americans benefit from high levels of health awareness and education, which increases acceptance and demand for immunizations such as the rotavirus vaccine. Public health campaigns increase awareness and adoption.
  • Furthermore, North America is home to numerous significant vaccine producers and research organizations that specialize in the development and production of rotavirus vaccines. The region's ability to innovate and produce underpins its dominant position in the global market.

Europe:

  • European countries have well-established, comprehensive immunization regimens that include rotavirus vaccines as part of the baby vaccination schedule. This government funding assures high immunization coverage and promotes regional market growth.
  • Europe has a high level of healthcare investment, which includes public health measures focused on the prevention of infectious diseases. The investment in healthcare infrastructure and preventive measures contributes to the widespread use of rotavirus vaccines.
  • European governments commonly work with international health organizations on vaccine procurement and distribution techniques, which aids in overcoming affordability and accessibility issues. These collaborations help to expand the implementation of immunization programs.
  • Furthermore, there is a great emphasis on public health education and awareness in Europe, which has resulted in higher vaccine acceptance rates among the general people. Educational efforts promoting the benefits of rotavirus vaccination boost demand and drive market expansion in the region.

Asia Pacific:

  • The Asia Pacific region is estimated to exhibit the highest growth during the forecast period. Asia Pacific has a high incidence of rotavirus infections, necessitating an urgent need for effective vaccinations. The high incidence of rotavirus-related illness and mortality among children in this region emphasizes the crucial need for extensive immunization campaigns.
  • Many countries in the Asia Pacific region are rapidly improving their healthcare infrastructure, increasing access to vaccines. Increased healthcare investments and immunization program expansion make it easier to distribute and administer rotavirus vaccines, hence driving market growth.
  • Rotavirus vaccination is becoming increasingly important in national immunization programs across the Asia Pacific. These programs, which are frequently funded by international health organizations, increase vaccine uptake and promote significant market growth.
  • Furthermore, Populations throughout the Asia Pacific are becoming more aware of the value of vaccination in preventing infectious diseases such as rotavirus. This greater awareness, combined with educational initiatives, drives demand for rotavirus vaccines, resulting in market growth.

Global Rotavirus Vaccine Market: Segmentation Analysis

The Global Rotavirus Vaccine Market is segmented based on Type, End-User, And Geography.

Rotavirus Vaccine Market, By Type

  • Rotarix
  • Rotavac
  • RotaTeq
  • Others

Based on Type, the market is segmented into Rotarix, Rotavac, RotaTeq, and Others. The RotaTeq segment is estimated to dominate the Rotavirus Vaccine Market due to its widespread acceptance and use in many countries, its efficacy in avoiding rotavirus gastroenteritis caused by the most frequent strains, and its inclusion in national immunization programs. Furthermore, its pentavalent formulation, which covers five rotavirus strains, provides broad protection, leading to its widespread use. Comprehensive safety and efficacy evidence, lengthy clinical trials, and recommendations from health authorities around the world all help to strengthen the vaccine's adoption.

Rotavirus Vaccine Market, By End-User

  • Hospitals
  • Clinics
  • Academics and Research Institutions
  • Others

Based on End-User, the market is segmented into Hospitals, Clinics, Academics and Research Institutions, and Others. The hospitals segment is estimated to hold the majority share in the forecast period of the Rotavirus Vaccine Market. Hospitals are primary healthcare venues where immunizations are provided, particularly to infants and young children, who receive the majority of rotavirus vaccines. The centralized nature of hospital facilities facilitates vaccine distribution and delivery, allowing a large number of people to be vaccinated in a controlled and medically monitored environment. Furthermore, hospitals frequently act as crucial centers of education for new parents about the need for vaccination, providing them with the information and resources they need to protect their children from rotavirus infection.

Key Players

  • The "Rotavirus Vaccine Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Merck & Co., GlaxoSmithKline plc, Walvax Biotechnology Co., Bharat Biotech International Limited, Institute of Vaccines and Medical Biologicals, Serum Institute of India Pvt. Ltd., Chengdu Institute of Biological Products Co., Beijing Wantai Biological Pharmacy Enterprise Co., Incheon Vaccines Ltd, Deyuan Biotech Group Co., Sanyou Biopharmaceuticals Co., Jilin Akeso Biopharmaceutical Co., CanSino Biologics Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd, Sanofi Pasteur and Pfizer Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

  • Rotavirus Vaccine Market Recent Developments
  • In November 2023, Medical Xpress reported a study finding that infants exposed to certain biologics during pregnancy can safely receive a rotavirus vaccine.
  • In January 2020, The Press Trust of India reported that the Serum Institute launched a new rotavirus vaccine in India, aiming to be a super-cheap option to combat childhood diarrhea.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL ROTAVIRUS VACCINE MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL ROTAVIRUS VACCINE MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model

5 GLOBAL ROTAVIRUS VACCINE MARKET, BY TYPE

  • 5.1 Overview
  • 5.2 Rotarix
  • 5.3 Rotavac
  • 5.4 RotaTeq
  • 5.5 Others

6 GLOBAL ROTAVIRUS VACCINE MARKET, BY END-USER

  • 6.1 Overview
  • 6.2 Hospitals
  • 6.3 Clinics
  • 6.4 Academic and Research
  • 6.5 Others

7 GLOBAL ROTAVIRUS VACCINE MARKET, BY GEOGRAPHY

  • 7.1 Overview
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 U.K.
    • 7.3.3 France
    • 7.3.4 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Rest of Asia Pacific
  • 7.5 Rest of the World
    • 7.5.1 Latin America
    • 7.5.2 Middle East and Africa

8 GLOBAL ROTAVIRUS VACCINE MARKET COMPETITIVE LANDSCAPE

  • 8.1 Overview
  • 8.2 Company Market Ranking
  • 8.3 Key Development Strategies

9 COMPANY PROFILES

  • 9.1 Merck & Co.
    • 9.1.1 Overview
    • 9.1.2 Financial Performance
    • 9.1.3 Product Outlook
    • 9.1.4 Key Developments
  • 9.2 GlaxoSmithKline plc.
    • 9.2.1 Overview
    • 9.2.2 Financial Performance
    • 9.2.3 Product Outlook
    • 9.2.4 Key Developments
  • 9.3 Beijing Wantai Biological Pharmacy Enterprise Co.
    • 9.3.1 Overview
    • 9.3.2 Financial Performance
    • 9.3.3 Product Outlook
    • 9.3.4 Key Developments
  • 9.4 Walvax Biotechnology Co.
    • 9.4.1 Overview
    • 9.4.2 Financial Performance
    • 9.4.3 Product Outlook
    • 9.4.4 Key Developments
  • 9.5 Bharat Biotech International Limited
    • 9.5.1 Overview
    • 9.5.2 Financial Performance
    • 9.5.3 Product Outlook
    • 9.5.4 Key Developments
  • 9.6 Institute of Vaccines and Medical Biologicals
    • 9.6.1 Overview
    • 9.6.2 Financial Performance
    • 9.6.3 Product Outlook
    • 9.6.4 Key Developments
  • 9.7 Serum Institute of India Pvt. Ltd.
    • 9.7.1 Overview
    • 9.7.2 Financial Performance
    • 9.7.3 Product Outlook
    • 9.7.4 Key Developments
  • 9.8 Chengdu Institute of Biological Products Co
    • 9.8.1 Overview
    • 9.8.2 Financial Performance
    • 9.8.3 Product Outlook
    • 9.8.4 Key Developments
  • 9.9 Incheon Vaccines Ltd
    • 9.9.1 Overview
    • 9.9.2 Financial Performance
    • 9.9.3 Product Outlook
    • 9.9.4 Key Developments
  • 9.10 Deyuan Biotech Group Co.
    • 9.10.1 Overview
    • 9.10.2 Financial Performance
    • 9.10.3 Product Outlook
    • 9.10.4 Key Developments

10 KEY DEVELOPMENTS

  • 10.1 Product Launches/Developments
  • 10.2 Mergers and Acquisitions
  • 10.3 Business Expansions
  • 10.4 Partnerships and Collaborations

11 APPENDIX

  • 11.1 Related Research